MAHMUT KARAPEHLİVAN, ERDOĞAN UZLU, ONUR ATAKİŞİ, HİDAYET METİN ERDOĞAN, METEHAN UZUN, MEHMET ÇİTİL

Doksorubisin uygulanan tavşanlarda plazma sialik asit, malondialdehit ve redükte glutatyon düzeylerine L-Karnitinin etkileri.

Antineoplastik bir ilaç olan doksorubisinin (DOX) tedavi dozunda oluşturduğu toksisiteye karşı L-karnitinin (LCAR) plazma Sialik asit (SA) ve MDA ile tam kan GSH düzeyleri üzerine koruyucu etkilerinin araştırılması amaçlandı. Çalışmada 21 adet sağlıklı Yeni Zelanda ırkı tavşan kullanıldı. Grup I’teki tavşanlara (n=8) 0.6 mg/kg dozda DOX, Grup II’teki tavşanlara (n=7) 0.6 mg/kg dozda DOX ile 1000 mg/kg dozda LCAR, Grup III’teki tavşanlara ise (n=6) 1000 mg/kg dozda LCAR 6 gün süreyle intraperitoneal yolla günde bir kez uygulandı. Tüm çalışma gruplarının uygulama öncesi 0. saatleri kontrol olarak değerlendirildi. Uygulama öncesi 0. saatte ve günlük ilaç uygulamalarından 2 saat sonra vena auricularis’ten kan örnekleri alındı. Grup I ile Grup II’deki tavşanlarda SA (TSA, LBSA) düzeylerinde uygulama boyunca uygulama öncesine göre önemli artışlar (P

Anahtar Kelimeler:

antineoplastik ajanlar, antioksidanlar, doksorubisin, ilaç toksisitesi, glutatyon, lipit peroksidasyonu, tavşan, siyalik asit

Effect of L-carnitine on plasma sialic acid, MDA and blood GSH levels in doxorubicine administered rabbits

The aim of this study is to determine the protective effect of L-carnitine (LCAR) against the toxicity of doxorubicin (DOX) an antineoplastic drug, treatment dose on plasma sialic acid (SA), malondialdehyde (MDA) and blood reducte glutathion (GSH) levels. In this study 21 healthy New Zealand rabbits were used. The rabbits in Group I (n=8) 0.6 mg/kg DOX, in Group II (n=7) 0.6 mg/kg DOX with 1000 mg/kg LCAR, in Group III (n=6) 1000 mg/kg dose were administered intra peritoneally along 6 days. In all groups the control groups were appreciated before administration. The blood samples were obtained after 2 h from administration. SA levels in Group I and in Group II significantly increased (P<0.001) during application than before administration, but SA levels in Group III decreased (P<0.001). GSH level in Group I decreased (P<0.05) from third day comparing to first day. GSH levels in Group III significantly increased (P<0.05) from second day of administration. MDA levels on 3, 4, 5 and 6th days of Group I incresead (P<0.001) when compared to first and second days and control group and GSH level increased (P<0.01) in Group II. MDA levels in Group III decreased (P<0.05) in all days. TSA and LBSA levels in Group I increased (P<0.001) comparing to Group II on 2, 3, 4, 5 and 6 th days of administration. GSH levels in Group III increased on 2 and 3rd days (P<0.01) and increased on 4, 5 and 6 th days (P<0.001) comparing to Group I and Group II. MDA levels in Group I increased on 1, 2, 4, 5 and 6 th days (P<0.001), on 3rd days (P<0.01) comparing to Group II. In conclusion, it may be suggested that L-carnitine administration could have a protective effect during doxorubisin administration through alteration plasma SA, MDA and blood GSH levels.

Keywords:

antineoplastic agents, antioxidants, doxorubicin, drug toxicity, glutathione, lipid peroxidation, rabbits, sialic acids,

PDF

___

Booser DJ, Hortobagyi GN: Anthracycline antibiotics in cancer therapy focus on drug resistance. Drugs, 47, 223-258, 1994.
Lown WJ: Anthracycline and anthraquinone anticancer agents: Current status and recent developments. Pharmacol Ther, 60, 185-214, 1993.
De Leonardis V, Neri B, Bacalli S, Cinelli P: Reduction of cardiac toxicity of anthracyclines by Lcarnitine. Int J Clin Pharmacol Res,5, 137-42, 1985.
Shug AL: Protection from adriamycine-induced cardiomyopathy in rats. Z Kardiol,76, 46-52, 1987.
Dorr RT: Cytoprotective agents for anthracycline. Semin Oncol, 23, 23-34, 1996.
Zhang J, Herman EH, Ferrans VJ: Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am J Pathol, 142, 1916-26, 1993.
Zhang J, Clark JR, Herman EH, Ferrans VJ: Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol,28, 1931-43, 1996.
Rebouche CJ: Carnitine function and requirements during the life cycle. Faseb J, 6, 3379-3386, 1992.
Fritz IB, Arrigoni-Martelli E: Sites of action of carnitine and its derivatives on the cardiovascular system. Interactions with membranes. Trend Pharmacol Sci, 14, 355-60, 1993.
Brass EM: Supplemental carnitine and exercise. Am J Clin Nutr,72, 618-623, 2000.
Ashraf V, Franco G, Syed I, Zbigniew B, Syed A: The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann N Y Acad Sci, 965, 225-232, 2002.
Citil M, Gunes V, Atakisi O, Ozcan A, Tuzcu M, Dogan A: Protective Effect of L-Carnitine against oxidative damage caused by experimental chronic aflatoxicosis in quail (Coturnix coturnix). Acta Vet Hung, 53(3): 319-324, 2005.
Kart A, Yapar K, Karapehlivan M, Citil M: The possible protective effect of L-carnitine on tilmicosininduced cardiotoxicity in mice. J Vet Med-A, 53, 1-3, 2006.
Frei B, Stocker R, Ames BN: Antioxidant defences and lipid peroxidation in human blood plasma. Proc Nat Acad Sci,85, 9748-9752, 1988.
Fernandez-Checa JC, Yi J, Ruiz CG, Ookhtens M, Kaplowitz N: Plasma membrane and mitochondrial transport of hepatic reduced glutathione. Semin liver Dis,16, 147-158, 1996.
Arockia Rani PJ, Panneerselvam C: L-carnitine as a free radical scavenger in aging. Exp Gerontol, 36, 1713- 1726, 2001.
Schauer R: Chemistry, metabolism and biological functions of sialic acid. Adv Carbohydr Chem Biochem, 40, 131-234, 1982.
Lindberg G, Eklund GA, Gullberg B, Rastam L: Serum sialic acid concentration and cardiovascular mortality. Br Med J,302, 143-146, 1991.
Haq M, Haq S, Tutt P, Crook M: Serum total sialic acid and lipid-associated sialic acid in normal induvals patients with myocardial infarction and their relationship to acut phase proteins. Ann Clin Biochem, 30, 383-386, 1993.
Crook M, Haq M, Haq S, Tutt P: Plasma Sialic acid and acute phase proteins in patients with myocardial infarction. Angiology,45(8): 709-715, 1994.
Sillanaukee P, Pönniö M, Jääskeläinen IP: Occurrence of sialic acids in healthy humans and different disorders. Eur J Clin Nutr, 29, 413-425, 1999.
Sydow G: A simplified quick method for determination of sialic acid in serum. Biomed Biochim Acta, 44, 1721- 1723, 1985.
Katopodis N, Stock C: Improved method to determine lipid bound sialic acid in plasma or serum. Res Commun Chem Pathol Pharmacol,30, 171-180, 1980.
Beutler E, Duran O, Kelley BM: Improved method for determination of blood glutathione. J Lab Clin Med, 61, 882-888, 1963.
Yoshoiko T, Kawada K, Shimada T: Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxigen toxicity in the blood. Am J Obstet Gynecol,135, 372-376, 1979.
Hanson VA, Shettigar UR, Loungani RR, Nadijcka MD: Plasma sialidase activity in acute myocardial infarction. Am Heart J, 114, 59-63, 1987.
Süer Gökmen S, Kılıçlı G, Özçelik F, Gülen Ş: Serum total and lipid-bound sialic acid levels following acute myocardial infarction. Clin Chem Lab Med,38(12): 1249-1255, 2000.
Paterna S, Furitano G, Scaffidi L, Barbarino C, Campisi D, Parisi G, Carreca I: Effects of L-carnitine on adriamycininduced cardiomyopathy in rabbit. Int J Tissue React,6, 91–95, 1984.
Thougard AV, Hellmen E, Jensen AL: Total Serum Sialic Acid is a General Disease Marker Rather than a Specific Tumour Marker in Dogs. J Vet Med A, 45, 471- 479, 1998.
Sayed Ahmed, M, Salman TM, Gaballah HE, Abou El-Naga SA, Nicolai R, Calvani M: Propionly-Lcarnitine as protector against adriamycin-induced cardiomyopathy. Pharmacol Res,43(6): 513-520, 2001.
Kawasaki N, Lee JD, Shimizu H, Ueda T: Long-term L-carnitine treatment prolongs the survival in rast with adriamycin-induced heart failure. J Cardiac Failure, 2, 293-299, 1996.
Hannun YA: Functions of ceramide in coordinating celluar responses to stress. Science, 274, 1855-1859, 1996.
Kolesnick RN, Kronke M: Regulation of ceramide production and apoptosis. Annu Rev Physiol, 60, 643- 665, 1998.
Di Marzio L, Alesse E, Roncaioli P, Muzi P, Moretti S, Marcellini S, Amicosante G, De Simone C, Cifone MG: Influence of L-carnitine on CD95 crosslinking- induced apoptosis and ceramide generation in human cell lines: correlation with its effects on purified acidic and neutral sphingomyelinases invitro. Proc Assoc Am Physicians,109, 154-63, 1997.
Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ: L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. Faseb J, 13, 1501- 1510, 1999.
Gutteridge JMC, Halliwel B: The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci,15, 129–135, 1990.
Kalaiselvi T, Panneersalvam C: Effect of L-carnitine on the status of lipid peroxidation and antioxidants in aging rats. J Nutr Biochem,9, 575–581, 1998.
Luo X, Reichhetzer B, Trinex J, Benson LN, Lehotay DC: L-carnitine attenuates doxorubicininduced lipid peroxidation in rats. Free Radic Biol Med, 26, 1156-1165, 1999.
Kaur J, Deepak S, Rameshwar S: Acetyl-L-carnitine enhances Na+, K+ATPase glutathione-s-transferase and multiple unit activity and reduces lipid peroxidation and lipofuscin concentration in aged rat brain regions. Neurosci Lett,301, 1-4, 2001.